Sagimet Biosciences (SGMT) Net Cash Flow (2022 - 2026)

Sagimet Biosciences' Net Cash Flow history runs 5 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 114.43% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at -$28.1 million (up 74.93% YoY), while the FY2025 annual figure was -$40.8 million, down 5922.97% from the prior year.
• Net Cash Flow was $1.6 million for Q1 2026 at Sagimet Biosciences, down from $2.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $101.6 million in Q1 2024 to a low of -$80.8 million in Q2 2024.
• Historically, Net Cash Flow has averaged $2.0 million across 5 years, with a median of -$1.6 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Net Cash Flow jumped 205766.67% in 2023, then tumbled 1409.85% in 2024.
• A 5-year view of Net Cash Flow shows it stood at -$2.1 million in 2022, then tumbled by 1166.15% to -$26.7 million in 2023, then surged by 95.6% to -$1.2 million in 2024, then surged by 315.08% to $2.5 million in 2025, then tumbled by 36.44% to $1.6 million in 2026.
• The last three Net Cash Flow figures came in at $1.6 million (Q1 2026), $2.5 million (Q4 2025), and -$9.8 million (Q3 2025), per Business Quant data.